Abstract: The present invention provides a novel bispecific anti-CD28 antibody format which is bivalent and comprises two CD28 binding sites, and at least one target binding site. The bispecific anti CD28 antibody of the invention is surprisingly advantageous due to its costimulatory activity which is strictly target cell restricted. The bispecific CD28 antibody of the invention is provided for use in the treatment of diseases either alone or in combination with a further bispecific antibody inducing a CD3/T cell receptor signal.

Abstract: The present invention relates to imidazo[4,5-c]quinoline compounds and to their use in the inhibition, regulation and/or modulation of signal transduction by ATM kinase and, in particular, for the treatment of ATM mediated diseases, especially cancer.

Abstract: The present invention relates to a protein having G-CSF-like activity comprising a) one or two polypeptide chains; b) a bundle of four ?-helices; and c) two or three amino acid linkers that connect contiguous bundle-forming ?-helices that are located on the same polypeptide chain, wherein each amino acid linker has a length between 2 and 20 amino acids. The invention also provides for a polynucleotide and a vector encoding the protein of the invention, host cells comprising said polynucleotide, a method for producing the protein of the invention and a pharmaceutical composition comprising the protein of the invention. The invention further relates to uses of the proteins of the invention as a research reagent and the use of the protein and/or pharmaceutical composition comprising the same as a medicament, e.g., for use in increasing stem cell production, for use in inducing hematopoiesis and/or for use in mobilizing hematopoietic stem cells.

Abstract: The present invention provides a novel PSMA binding antibody termed 10B3 and pharmaceutical and diagnostic uses of the antibody 10B3. The PSMA antibody 10B3 does not cross-compete with the state of the art PMSA binding antibody J591 and has a reduced induction of antigen shift compared to J591 and a unique reactivity with squamous cell carcinoma (SCC) cells of different origin.

Abstract: The present invention relates to novel inhibitors of the shikimate pathway (shikimic acid pathway), pharmaceutical compositions comprising these novel inhibitors, methods for the production of the inhibitors and their use as antibiotics and herbicides.

Abstract: The present invention is in the field of the cultivation of biological cells and tissues with organ-like function on a microphysiological scale and provides a method for the microphysiological co-cultivation of 3D organoid tissue and at least one 2D cell layer.

Abstract: The present invention relates to a nucleotide-modified messenger RNA for the permanent correction of a genetic alteration on a DNA. The invention further relates to a nucleotide-modified messenger RNA in combination with a repair template. It also relates to a pharmaceutical composition. It finally relates to methods for the correction of a genetic alteration on a DNA.

Abstract: A method is used for determining a status of an encapsulation and/or a passivation layer of the encapsulation. The encapsulation forms a multi-layer system from multiple passivation layers arranged on top of one another and electrically contacted intermediate layers arranged between the passivation layers. The multi-layer system protects an implant surrounded by the encapsulation. In the method, an electrical measurement is carried out between a reference potential and at least one electrically contacted intermediate layer, and at least one current flowing between the reference potential and the at least one electrically contacted intermediate layer is detected. The at least one detected current is compared with at least one pre-determined threshold value. If the detected current falls below or exceeds the at least one threshold value, this indicates a functional state of a passivation layer adjacent to the at least one electrically contacted intermediate layer.

Abstract: The present invention relates to a method for determining in a subject's biological sample the relative proportions of papillary renal cell carcinoma (pRCC), clear cell renal cell carcinoma (ccRCC), and chromophobe renal cell carcinoma (chRCC), an array comprising capture molecules capable of specifically binding to RCC signature genes or coding sequences thereof or products encoded thereby, and the use of RCC signature genes for classifying a subject into a renal cell carcinoma (RCC) risk group and/or for determining in a subject's biological sample the relative proportions of pRCC, ccRCC, and chRCC.

Abstract: A nucleic acid molecule can code for an Orf virus vector promoter. A recombinant Orf virus vector can be included in a cell. The nucleic acid molecule, the vector and/or the cell can be included in a composition. The recombinant Orf virus vector can be used for the production of a foreign gene.

Abstract: The present disclosure is related to improved methods for use of a humanized binding polypeptide specific for the alpha beta T cell receptor (??-TCR). In particular, this disclosure relates to improved methods of use of a humanized anti-??-TCR antibody, which is derived from the murine monoclonal antibody BMA031, in immunosuppressive therapy. Novel methods using humanized monoclonal antibodies and/or humanized monoclonal antibody fragments (e.g., anti-??TCR antibodies and/or fragments thereof) are also provided. Novel methods using repetitive administration of humanized monoclonal antibodies and/or humanized monoclonal antibody fragments (e.g., anti-??TCR antibodies and/or fragments thereof) to reduce ?? T cells in the subject relative to ?? cells in the subject are provided.

Abstract: The present invention relates to a nucleic acid molecule which encodes a splice variant of the human P2RX7 receptor, and nucleic acid molecules derived therefrom, a recombinant vector containing said nucleic acid molecules, a host containing said recombinant vector, a polypeptide encoded by said nucleic acid molecules, a host cell expressing said polypeptide, a binding molecule binding to said polypeptide, a pharmaceutical composition comprising said binding molecule, a method for the production of the isolated polypeptide, and other methods and uses in connection therewith.

Abstract: The automated determination of an individual function of a DPOAE level map with pdp,I=f(L1, L2) of human or animal hearing. The method may include reading into a main memory a model function with model parameters of a DPOAE level map, based upon a number of N DPOAE measurements of a stimulation frequency pair with respectively different level pairs in a population (p) of a population of normally hearing subjects, automatically presenting n different level pairs of a stimulation frequency pair via tone output means to an individual and detecting the corresponding DPOAE's of the individual via tone recording means, wherein at least the first level pair is predefined, iteratively adapting the model function to the measured n DPOAE's until an individual function is obtained with individual parameters of a DPOAE level map of the individual, outputting the individual function and/or its individual parameters.

Abstract: The present invention relates to fusion proteins comprising a binding protein and an IL-15 polypeptide as well as uses thereof, pharmaceutical compositions comprising such fusion proteins and a method for producing such fusion proteins.

Abstract: The present invention is in the field of the cultivation of biological cells and tissues with organ-like function on a microphysiological scale and provides a method for the microphysiological co-cultivation of 3D organoid tissue and at least one 2D cell layer.

Abstract: The invention relates to a plant having increased resistance to pathogens, wherein the protein SOBIR1 from Arabidopsis thaliana or a homologous protein, which is capable of interacting with at least one of the PRR receptor proteins RLP30 or RLP1, and at least one of the PRR receptor proteins RLP30 or RLP1 are overexpressed in comparison with the wild-type plant or are newly synthesized. The pathogens are preferably fungi, in particular from the genus Sclerotinia, and bacteria, in particular from the genus Xanthomonas. The invention further relates to a method for producing a plant having increased resistance to pathogens.

Abstract: In a method for examining the faculty of hearing for at least one ear of a mammal, in which growth curves are determined on the basis of the measurement of DPOAE's evoked by pairs of excitation signals (f1, f2) for different excitation frequencies f2, the ear is presented with first excitation signals with a first excitation frequency f1 and a first noise level L1 and secondary excitation signals with a second excitation frequency f2 and a second noise level L2. Pulse pairs with a first pulse of the first excitation signal and a second pulse of the second excitation signal are presented in the ear, and the DPOAE's evoked thereby are captured and evaluated. A set of at least two different pulse pairs with different second excitation frequencies f2 is presented in one block that is repeated several times during a measuring period.

Abstract: The present invention relates to a nucleotide-modified messenger RNA for the permanent correction of a genetic alteration on a DNA. The invention further relates to a nucleotide-modified messenger RNA in combination with a repair template. It also relates to a pharmaceutical composition. It finally relates to methods for the correction of a genetic alteration on a DNA.

Abstract: In a hearing aid (26) that can be inserted into the ear canal (12) of a patient, comprising an actuator (31) effecting a mechanical stimulation of the tympanic membrane (14), the actuator (31) comprises an inner surface (32) associated with the tympanic membrane (14) and an outer surface (42) associated with the ear canal (12) and is configured as an areal disk actuator, whose deformation stimulates the tympanic membrane (14) by areal deformation. On the actuator (31) at a distance from the outer surface (42) a cover plate (43) is arranged which together with the outer surface (42) delimits a preferably lenticular cavity (48).

Abstract: The invention relates to compositions and methods that utilize polymeric nanoparticles to deliver a therapeutic compound to ocular cells or ocular tissue. Provided is a drug-loaded micelle comprising self-assembled amphiphilic biopolymers, such as hydrophobically modified nucleic acids or polypeptides, for use as ophthalmic drug delivery system. Also provided are ophthalmic compositions and methods for preventing or treating an ophthalmic disease.